These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 23587459)

  • 21. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.
    Garcia-Manero G; Abaza Y; Takahashi K; Medeiros BC; Arellano M; Khaled SK; Patnaik M; Odenike O; Sayar H; Tummala M; Patel P; Maness-Harris L; Stuart R; Traer E; Karamlou K; Yacoub A; Ghalie R; Giorgino R; Atallah E
    Blood Adv; 2019 Feb; 3(4):508-518. PubMed ID: 30760466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
    Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
    J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare network.
    Bories P; Bertoli S; Bérard E; Laurent J; Duchayne E; Sarry A; Delabesse E; Beyne-Rauzy O; Huguet F; Récher C
    Am J Hematol; 2014 Dec; 89(12):E244-52. PubMed ID: 25195872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of acute myeloid leukaemia in older patients - scope of intensive therapy? - A retrospective analysis.
    Mayer K; Serries M; Hahn-Ast C; Bisht S; Brossart P; Feldmann G
    Hematology; 2023 Dec; 28(1):2212536. PubMed ID: 37204122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Azacitidine for the treatment of relapsed and refractory AML in older patients.
    Itzykson R; Thépot S; Berthon C; Delaunay J; Bouscary D; Cluzeau T; Turlure P; Prébet T; Dartigeas C; Marolleau JP; Recher C; Plantier I; Stamatoullas A; Devidas A; Taksin AL; Guièze R; Caillot D; Vey N; Adès L; Ifrah N; Dombret H; Fenaux P; Gardin C
    Leuk Res; 2015 Feb; 39(2):124-30. PubMed ID: 25524177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
    Quintás-Cardama A; Ravandi F; Liu-Dumlao T; Brandt M; Faderl S; Pierce S; Borthakur G; Garcia-Manero G; Cortes J; Kantarjian H
    Blood; 2012 Dec; 120(24):4840-5. PubMed ID: 23071272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy.
    Leroy H; Gadaud N; Bérard E; Klein E; Luquet I; Vial JP; Rieu JB; Lechevalier N; Tavitian S; Leguay T; Largeaud L; Bidet A; Delabesse E; Sarry A; de Grande AC; Récher C; Pigneux A; Bertoli S; Dumas PY
    Cancer Med; 2024 Feb; 13(3):e7003. PubMed ID: 38400682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
    Tikhonova IA; Hoyle MW; Snowsill TM; Cooper C; Varley-Campbell JL; Rudin CE; Mujica Mota RE
    Pharmacoeconomics; 2017 Mar; 35(3):363-373. PubMed ID: 27752999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
    Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
    Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.
    Vachhani P; Al Yacoub R; Miller A; Zhang F; Cronin TL; Ontiveros EP; Thompson JE; Griffiths EA; Wang ES
    Leuk Res; 2018 Dec; 75():29-35. PubMed ID: 30445237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study.
    Krug U; Koschmieder A; Schwammbach D; Gerss J; Tidow N; Steffen B; Bug G; Brandts CH; Schaich M; Röllig C; Thiede C; Noppeney R; Stelljes M; Büchner T; Koschmieder S; Dührsen U; Serve H; Ehninger G; Berdel WE; Müller-Tidow C
    PLoS One; 2012; 7(12):e52695. PubMed ID: 23300745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
    Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
    Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of the Overall Survival with Azacitidine Monotherapy in Untreated Acute Myeloid Leukemia Patients Ineligible for Intensive Therapy.
    Taenaka R; Obara T; Kohno K; Aoki K; Ogawa R
    Intern Med; 2023 Mar; 62(5):689-695. PubMed ID: 35871587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients.
    Hilberink J; Hazenberg C; van den Berg E; Mulder A; Schuringa JJ; van der Helm L; de Groot M; Choi G; de Bock GH; Vellenga E; Ammatuna E; Huls G
    Leuk Res; 2019 May; 80():33-39. PubMed ID: 30954622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.
    Roboz GJ; Sanz G; Griffiths EA; Yee K; Kantarjian H; Récher C; Byrne MT; Patkowska E; Kim HJ; Thomas X; Moors I; Stock W; Illés Á; Fenaux P; Miyazaki Y; Yamauchi T; O'Connell CL; Hao Y; Keer HN; Azab M; Döhner H
    Blood Adv; 2024 Apr; 8(8):2020-2029. PubMed ID: 38231126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy.
    Yoshida C; Kondo T; Ito T; Kizaki M; Yamamoto K; Miyamoto T; Morita Y; Eto T; Katsuoka Y; Takezako N; Uoshima N; Imada K; Ando J; Komeno T; Mori A; Ishikawa Y; Satake A; Watanabe J; Kawakami Y; Morita T; Taneike I; Nakayama M; Duan Y; Garbayo Guijarro B; Delgado A; Llamas C; Kiyoi H
    Int J Hematol; 2022 Jul; 116(1):89-101. PubMed ID: 35394258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.
    Winters AC; Gutman JA; Purev E; Nakic M; Tobin J; Chase S; Kaiser J; Lyle L; Boggs C; Halsema K; Schowinsky JT; Rosser J; Ewalt MD; Siegele B; Rana V; Schuster S; Abbott D; Stevens BM; Jordan CT; Smith C; Pollyea DA
    Blood Adv; 2019 Oct; 3(20):2911-2919. PubMed ID: 31648312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia.
    Seymour JF; Döhner H; Minden MD; Stone R; Gambini D; Dougherty D; Beach CL; Weaver J; Dombret H
    Leuk Lymphoma; 2017 Jun; 58(6):1412-1423. PubMed ID: 27739920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Real-Life Efficacy of Fixed-Dose Hypomethylating Agents in Older Patients With Acute Myeloid Leukemia: A 10-Year Experience.
    Rungjirajittranon T; Kungwankiattichai S; Kunacheewa C; Owattanapanich W
    Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):852-860. PubMed ID: 34364821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.